FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211091719> ?p ?o ?g. }

• W3211091719 abstract "Neurological disability progression occurs across the spectrum of people living with multiple sclerosis (MS). Although there are a handful of disease-modifying treatments approved for use in progressive phenotypes of MS, there are no treatments that substantially modify the course of clinical progression in MS. Characterizing the determinants of clinical progression can inform the development of novel therapeutic agents and treatment approaches that target progression in MS, which is one of the greatest unmet needs in clinical practice. Canada, having one of the world's highest rates of MS and a publicly-funded health care system, represents an optimal country to achieve in-depth analysis of progression. Accordingly, the overarching aim of the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo) is to evaluate a wide spectrum of factors associated with the clinical onset and rate of disease progression in MS, and to describe how these factors relate to one another to influence progression.CanProCo is a prospective, observational cohort study with investigators specializing in epidemiology, neuroimaging, neuroimmunology, health services research and health economics. CanProCo's study design was approved by an international review panel, comprised of content experts and key stakeholders. One thousand individuals with radiologically-isolated syndrome, relapsing-remitting MS, and primary-progressive MS within 10-15 years of disease onset will be recruited from 5 academic MS centres in Canada. Participants will undergo detailed clinical evaluation annually over 5 years (including advanced, app-based clinical data collection). In a subset of participants within 5-10 years of disease onset (n = 500), blood, cerebrospinal fluid, and research MRIs will be collected allowing an integrated, in-depth evaluation of factors contributing to progression in MS from multiple perspectives. Factors of interest range from biological measures (e.g. single-cell RNA-sequencing), MRI-based microstructural assessment, participant characteristics (self-reported, performance-based, clinician-assessed, health-system based), and micro and macro-environmental factors.Halting the progression of MS remains a fundamental need to improve the lives of people living with MS. Achieving this requires leveraging transdisciplinary approaches to better characterize why clinical progression occurs. CanProCo is a pioneering multi-dimensional cohort study aiming to characterize these determinants to inform the development and implementation of efficacious and effective interventions." @default.
• W3211091719 created "2021-11-08" @default.
• W3211091719 creator A5001735285 @default.
• W3211091719 creator A5001868151 @default.
• W3211091719 creator A5004665009 @default.
• W3211091719 creator A5008771598 @default.
• W3211091719 creator A5012087557 @default.
• W3211091719 creator A5012744052 @default.
• W3211091719 creator A5030980805 @default.
• W3211091719 creator A5048931275 @default.
• W3211091719 creator A5061657335 @default.
• W3211091719 creator A5073011666 @default.
• W3211091719 creator A5079991612 @default.
• W3211091719 creator A5080958470 @default.
• W3211091719 creator A5084754494 @default.
• W3211091719 creator A5085566077 @default.
• W3211091719 creator A5090878663 @default.
• W3211091719 date "2021-10-27" @default.
• W3211091719 modified "2023-10-08" @default.
• W3211091719 title "The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design" @default.
• W3211091719 cites W1567125068 @default.
• W3211091719 cites W1978243650 @default.
• W3211091719 cites W2018693879 @default.
• W3211091719 cites W2026877602 @default.
• W3211091719 cites W2030113529 @default.
• W3211091719 cites W2038909771 @default.
• W3211091719 cites W2043705607 @default.
• W3211091719 cites W2058583207 @default.
• W3211091719 cites W2059796825 @default.
• W3211091719 cites W2066227952 @default.
• W3211091719 cites W2103559424 @default.
• W3211091719 cites W2112165124 @default.
• W3211091719 cites W2120265437 @default.
• W3211091719 cites W2132322340 @default.
• W3211091719 cites W2150378783 @default.
• W3211091719 cites W2159069244 @default.
• W3211091719 cites W2257766930 @default.
• W3211091719 cites W2325647314 @default.
• W3211091719 cites W2332489744 @default.
• W3211091719 cites W2489432788 @default.
• W3211091719 cites W2512303823 @default.
• W3211091719 cites W2588929689 @default.
• W3211091719 cites W2591088516 @default.
• W3211091719 cites W2593373425 @default.
• W3211091719 cites W2751736380 @default.
• W3211091719 cites W2777074421 @default.
• W3211091719 cites W2781755133 @default.
• W3211091719 cites W2791064447 @default.
• W3211091719 cites W2942648909 @default.
• W3211091719 cites W2942914854 @default.
• W3211091719 cites W2950296939 @default.
• W3211091719 cites W2952221403 @default.
• W3211091719 cites W2964240868 @default.
• W3211091719 cites W3003219405 @default.
• W3211091719 cites W3033968144 @default.
• W3211091719 cites W3043029189 @default.
• W3211091719 cites W2166352864 @default.
• W3211091719 doi "https://doi.org/10.1186/s12883-021-02447-7" @default.
• W3211091719 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8549411" @default.
• W3211091719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34706670" @default.
• W3211091719 hasPublicationYear "2021" @default.
• W3211091719 type Work @default.
• W3211091719 sameAs 3211091719 @default.
• W3211091719 citedByCount "1" @default.
• W3211091719 countsByYear W32110917192023 @default.
• W3211091719 crossrefType "journal-article" @default.
• W3211091719 hasAuthorship W3211091719A5001735285 @default.
• W3211091719 hasAuthorship W3211091719A5001868151 @default.
• W3211091719 hasAuthorship W3211091719A5004665009 @default.
• W3211091719 hasAuthorship W3211091719A5008771598 @default.
• W3211091719 hasAuthorship W3211091719A5012087557 @default.
• W3211091719 hasAuthorship W3211091719A5012744052 @default.
• W3211091719 hasAuthorship W3211091719A5030980805 @default.
• W3211091719 hasAuthorship W3211091719A5048931275 @default.
• W3211091719 hasAuthorship W3211091719A5061657335 @default.
• W3211091719 hasAuthorship W3211091719A5073011666 @default.
• W3211091719 hasAuthorship W3211091719A5079991612 @default.
• W3211091719 hasAuthorship W3211091719A5080958470 @default.
• W3211091719 hasAuthorship W3211091719A5084754494 @default.
• W3211091719 hasAuthorship W3211091719A5085566077 @default.
• W3211091719 hasAuthorship W3211091719A5090878663 @default.
• W3211091719 hasBestOaLocation W32110917191 @default.
• W3211091719 hasConcept C107130276 @default.
• W3211091719 hasConcept C118552586 @default.
• W3211091719 hasConcept C126322002 @default.
• W3211091719 hasConcept C12770488 @default.
• W3211091719 hasConcept C16568411 @default.
• W3211091719 hasConcept C188816634 @default.
• W3211091719 hasConcept C201903717 @default.
• W3211091719 hasConcept C23131810 @default.
• W3211091719 hasConcept C2779134260 @default.
• W3211091719 hasConcept C512399662 @default.
• W3211091719 hasConcept C535046627 @default.
• W3211091719 hasConcept C71924100 @default.
• W3211091719 hasConcept C72563966 @default.
• W3211091719 hasConcept C74909509 @default.
• W3211091719 hasConceptScore W3211091719C107130276 @default.
• W3211091719 hasConceptScore W3211091719C118552586 @default.
• W3211091719 hasConceptScore W3211091719C126322002 @default.
• W3211091719 hasConceptScore W3211091719C12770488 @default.

• next